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prospectively collected data on 1958 consecutive HSCTs per-
formed between 1995 and 2004 and compared patients with
DAH and infection associated alveolar hemorrhage (IAH) who
presented with similar hypoxemia, pulmonary inﬁltrates, and
progressively bloody alveolar lavage but also had microorgan-
isms (excluding Aspergillus spp) isolated from blood, bronchoal-
veolar lavage (BAL), or tracheal aspirate within 1 week of
alveolar hemorrhage. Overall, 116 (5.9%) patients had alveolar
hemorrhage diagnosed by BAL (DAH  45, IAH  71). Sixty-
day mortality from the onset of alveolar hemorrhage was 74%
(95% conﬁdence-interval (CI), 66–82%). For the whole cohort,
presence of infection (P  .04) and hemorrhage within 5 days of
engraftment (P  .01) were predictive of survival beyond 60
days from onset of alveolar hemorrhage. The DAH and IAH
groups were comparable except for greater use of total body
irradiation containing conditioning regimen in the DAH group
(P  .04) and umbilical cord blood donor source in the IAH
group (P  .04). Survival at 60 days from the onset of alveolar
hemorrhage was 16% (95% CI, 5–27%) for the DAH group and
32% (95% CI, 21%–43%) for the IAH group (P  .18). All
except 20 patients (DAH  4, IAH  16) were treated with a
standard regimen of high-dose corticosteroids. The steroid and
no-steroid groups were comparable except for a trend towards
greater use of corticosteroids in the DAH group (P  .06). Sixty
day survival from the onset of alveolar hemorrhage was 26%
(95% CI, 17–35%) in patients receiving corticosteroids com-
pared to 25% (95% CI, 6–44%) in those not receiving corti-
costeroids (P  .17). The pathogenesis of alveolar hemorrhage
following HSCT is multifactorial and we propose that IAH and
DAH are related clinical syndromes with similar clinical pre-
sentation, risks, and associated high mortality. Furthermore, our
results show no beneﬁt of high-dose corticosteroids in the
management of this disorder. Ongoing study to identify the
pathophysiologic mechanisms of alveolar injury and to deﬁne
new therapy is still needed.
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POSACONAZOLE (POS) VS FLUCONAZOLE (FLU) FOR PROPHYLAXIS OF
INVASIVE FUNGAL INFECTIONS (IFIs) IN ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS WITH GRAFT-VER-
SUS-HOST DISEASE (GVHD): A MULTICENTER TRIAL
Durrant, S.1, Vesole, D.2, Langston, A.3, Lipton, J.H.4, Patino, H.5,
Pedicone, L.5, Ullmann, A.J.6 1. Royal Brisbane Hospital, Brisbane,
Australia; 2. Medical College of Wisconsin, Milwaukee, WI; 3. Emory
University Hospital, Atlanta, GA; 4. Princess Margaret Hospital, To-
ronto, ON, Canada; 5. Schering-Plough Research Institute, Kenilworth,
NJ; 6. Johannes Gutenberg University, Mainz, Germany.
Introduction: Allogeneic HSCT recipients are at risk for life-
threatening IFI. In patients with GVHD, IFIs are mainly due to
moulds, limiting the utility of prophylactic FLU. We compared
POS with FLU in preventing IFI in HSCT recipients with GVHD
on intensive immunosuppressives. Methods: Patients in this dou-
ble-blind, double-dummy study received oral POS (200 mg tid) or
FLU (400 mg qd) for up to 16 weeks (112 days). Incidence of IFI
was determined at 16 weeks and up to 7 days after last dose by
EORTC/MSG criteria adjudicated by a blinded expert panel. Re-
sults: 600 patients were enrolled (301 POS; 299 FLU). Mean
duration of therapy was 80 days in the POS arm and 77 days in the
FLU arm. Incidence of proven/probable IFIs is shown below.
Mortality rate due to IFI was POS (1%) versus FLU (4%); overall
rate was 25% versus 28%. Safety and tolerability were comparable.
Discontinuations due to treatment failure were lower for POS
versus FLU (3% vs 8%); those due to adverse events were similar
(33% each).Conclusions: POS was superior to FLU in preventing
aspergillosis and other breakthrough IFIs in HSCT recipients with
GVHD. Although POS was noninferior to FLU in preventing
total IFIs during the study period, the criteria for superiority were
not met. This may be because of the high rate of discontinuation
before day 112 (45% of POS patients and 52% of FLU patients),
contributing to the small number of IFI events. Both agents were
well tolerated (Table1).
Table 1.
Proven/Probable IFIs
POS,
n (%)
FLU,
n (%)
Odds Ratio
(95% CI)
P
Value
IFIs during study period (day 112)
Total 16 (5) 27 (9) 0.56 (0.30–1.1) .07
Aspergillus 7 (2) 21 (7) 0.31 (0.13–0.75) .006
Breakthrough infections (while on treatment)
Total 7 (2) 22 (8) 0.30 (0.12–0.71) .004
Aspergillus 3 (1) 17 (6) 0.17 (0.05–0.57) .001
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ACTIVE TREATMENT OF ASYMPTOMATIC RADIOLOGICALLY DOCU-
MENTED SINUSITIS MAY BE NECESSARY FOR PATIENTS RECEIVING
TOTAL BODY IRRADIATION CONDITIONING
Kwon, J.M.1, Jung, C.W.1, Kim, W.S.1, Kim, K.M.1, Chung, S.K.1,
Kang, W.K.1, Park, K.1 Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea.
Background: In hematopoietic stem cell transplantation
(HSCT), careful evaluation of paranasal sinus is necessary be-
cause increased risk of sinusitis may be problematic during
post-transplant neutropenic period. However, there are no cri-
teria for diagnosis and optimal treatment of asymptomatic ra-
diologically documented or symptomatic sinusitis. Methods: A
retrospective review of the medical records of 256 patients who
received autologous (n  124) or allogeneic (n  128) HSCT
for hematologic malignancies at Samsung Medical Center from
April 1996 to December 2003 was performed. Four patients
were excluded because of tumor originated in nasal cavity.
Radiologically documented sinusitis was deﬁned as mucosal
thickening, opaciﬁcation and air-ﬂuid level of sinus without
symptom. Symptomatic sinusitis was deﬁned as symptoms such
as postnasal drip, rhinorrhea, nasal obstruction, cough, fever,
headache with radiologic abnormalities.
Results: The median age was 38 years (range 15–68 years). One
hundred thirty-three (52.8%) of 252 patients had no evidence of
sinusitis and 23 (9.1%) patients had symptomatic sinusitis before
transplantation. The remaining 96 patients (38.1%) had asymp-
tomatic radiologically documented sinusitis. All symptomatic si-
nusitis were treated sufﬁciently before proceeding to HSCT. Of 96
patients with radiologically documented sinusitis, but without
symptom, 54 were treated with antibiotics, 6 were operated endo-
scopically, and 36 were not treated.
After transplantation, sinusitis developed in 76 patients (30.2%), 40
(15.9%) were documented clinically and 36 (14.3%) were radiologi-
cally. Median day of onset of sinusitis was 52.5 days (range 1–420
days) after transplantation. There were no deaths or graft failure
related to sinus complications. In patients with asymptomatic radio-
logically documented sinusitis, there was no difference in the inci-
dence of post-transplant sinusitis among surgery and medical therapy
and observation (P  .479). In patients who received total body
irradiation (TBI) as conditioning regimen, radiologically documented
sinusitis was related to higher risk of developing post-transplantation
sinusitis (P  .033). Conclusions: Our data suggest that aggressive
treatment of asymptomatic radiologically documented sinusitis at pre-
transplantation may not be necessary. However, if recipient is sched-
uled to receive of TBI as conditioning regimen, active treatment of
asymptomatic radiologically documented sinusitis is to be considered.
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ACUTE GRAFT-VERSUS-HOST DISEASE AND IMMUNOSUPPRESSIVE
THERAPY IDENTIFY PATIENTS LESS LIKELY TO HAVE A DIAGNOSTIC
YIELD WITH A BRONCHOALVEOLAR LAVAGE: THE ST. JUDE EXPERI-
ENCE 1990–2002
Kasow, K.A.1, King, E.2, Rochester, R.J.1, Tong, X.1, Srivastava, D.K.1,
Horwitz, E.M.1, Leung, W.1, Woodard, P.1, Handgretinger, R.1,
Hale, G.A.1 1. St. Jude Children’s Reseach Hospital, Memphis, TN; 2.
Chicago College of Osteopathic Medicine, Downers Grove, IL.
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Background: Pulmonary complications after hematopoietic
stem cell transplantation (HSCT) are common, and manage-
ment may include a bronchoalveolar lavage (BAL). We reviewed
the medical records of patients (pts) who underwent a BAL and
HSCT at our institution from 1990 to 2002 to determine the
success of BAL and identify factors that may alter the diagnostic
yield of the procedure. Methods: Of 917 pts undergoing HSCT
during this period, 90 pts underwent BAL after HSCT. Multiple
data points were analyzed to determine factors that may identify
a patient population more or less likely to have a diagnostic yield
from a BAL. Results: 114 procedures were performed during
this period. The mean age was 12.5 years (range 0.75–26.2
years). For those who had more than 1 BAL performed, only the
ﬁrst procedure was included in the analysis. The BAL was
performed at a mean of 93 days post-HSCT (range 6–730 days).
The 3 most common signs/symptoms leading to the procedure
were fever (56.7%), hypoxia (48.9%), and abnormal chest aus-
cultation (44.4%). Prior to BAL, 88 pts had radiological imag-
ing; 82 pts (93%) had abnormal ﬁndings. The most common
pre-BAL diagnosis was pneumonia (43.3%) followed by respi-
ratory distress (14.4%). Twenty-nine pts (32.2%) had a negative
BAL. The most common ﬁnding was a bacterial infection
(58.9%), followed by an inﬂammatory process (18.9%), viral
infection (13.3%), and alveolar hemorrhage (12.2%). Of the 44
pts who had concurrent infections, 34 (77%) had positive BAL;
82.2% of pts did not experience any procedural complications,
and 10% experienced hypoxia, generally transient. Sixty-seven
pts were receiving immunosuppressive therapy (IST) at the time
of BAL. Twenty-seven of twenty-nine (93.1%) pts who had a
negative BAL were receiving IST compared to 40/61 (65.6%)
pts who had a positive BAL and were on IST (P  .0046).
Furthermore, the proportion of pts who had grade 2–4 acute
graft-versus-host disease (GVHD) was signiﬁcantly higher in
the BAL negative population (13/29  44.8%) than the BAL
positive group (14/61  23%) [P  .0487]. No other prognostic
factors were identiﬁed for those with grade 2–4 GVHD. Con-
clusions: In our experience, performing a BAL after HSCT is
safe. For patients with grade 2–4 acute GVHD or receiving
IST, the likelihood of a respiratory etiology being identiﬁed by
BAL is lower than those without these risk factors. Therefore, in
this particular patient population, a BAL is less likely to have a
diagnostic yield and may not impact therapy.
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ASSESSMENT OF SYMPTOMS AND SYMPTOM BURDEN BEFORE AND
AFTER ENGRAFTMENT DURING ALLOGENEIC BLOOD OR MARROW
TRANSPLANT (BMT)
Williams, L.A.1, Wang, X.S.1, Cleeland, C.S.1, Mobley, G.1, Giralt, S.1
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Symptom burden (SB) is the combined impact of all disease- or
therapy-related symptoms on one’s ability to function as one did
before onset of disease or therapy. Patient report of symptoms
following BMT is not well-described. Lack of understanding of
symptoms and SB may result in failure to address symptoms and
return patients to optimum functioning. Purpose: To describe
symptoms and SB in AML/MDS patients undergoing allogeneic
BMT before and after neutrophil engraftment (ﬁrst of 3 consecu-
tive days ANC  500 cells/mm3). Methods: 30 patients with a
mean age of 52.9 years (SD  9.6) rated 19 symptoms on a 0–10
scale twice weekly from baseline before the start of conditioning to
28 days post-BMT using the M. D. Anderson Symptom Inventory.
Results: Mean global symptom severity (GSS) peaked at day 11
post-BMT. The 7 most severe symptoms on day 11 were pain,
drowsiness, lack of appetite, dry mouth, mouth sores, physical
weakness, and fatigue. Mean symptom intensity scores and SDs are
reported in Table 1. There was a signiﬁcant difference (t  4.34,
P .001) between mean GSS at baseline and day11. Neutrophil
engraftment occurred on average 13.7 days (SD  3.00) post-
BMT. There was no signiﬁcant difference (t  0.75, P  .455) in
mean GSS from day 11 to day 15, the ﬁrst post-engraftment
assessment. Mean GSS declined by day 29, but the difference
between the mean GSS on day 11 and day 29 was not signif-
icant (t 1.92, P .060). At day15, only mean pain severity had
declined signiﬁcantly (t  2.48, P  .016) from day 11. At day
29, mean pain and mouth sores severity had declined signiﬁcantly
(t  4.46, P  .001 and t  2.26, P  .031, respectively) from day
11. Conclusions: Patients report various symptoms post-alloge-
neic BMT, with the most severe involving pain, the upper GI tract,
fatigue, and weakness. After engraftment, pain severity declines
rapidly, GI symptoms decline more slowly, and fatigue and weak-
ness do not decline. Most symptoms have not declined signiﬁcantly
a month post-BMT and patients remain burdened by symptoms.
Clinicians should verify with patients the symptoms they are ex-
periencing and intervene to control them. Further research in SB
and in the causative mechanisms of symptoms is needed to improve
BMT treatment outcomes.
Table 1. Mean Symptom Severity Scores
Baseline Day 11 Day 15 Day 29
Symptom Mean, SD Mean, SD Mean, SD Mean, SD
GSS 1.32,1.38 3.08,1.74 2.72,1.91 2.24,1.59
Pain 1.80,2.91 5.30,2.68 3.52,2.84 2.29,2.45
Drowsiness 1.87,2.50 5.20,2.89 4.48,3.00 3.75,3.08
Lack of appetite 1.10,2.22 4.57,3.18 4.14,3.32 3.18,2.88
Dry mouth 0.87,1.61 4.52,3.21 3.97,3.52 2.93,3.21
Mouth sores 0.03,0.18 4.50,3.95 2.93,3.21 0.82,2.06
Physical weakness 2.03,2.55 4.37,2.86 3.83,2.90 3.96,2.76
Fatigue 3.00,2.29 4.20,2.57 4.41,2.78 4.46,2.82
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A CLINICAL ALGORITHM FOR CIDOFOVIR TREATMENT OF ADENOVIRAL
INFECTIONS IN PEDIATRIC ONCOLOGY AND BONE MARROW TRANS-
PLANT PATIENTS: A REPORT OF DIRECTED, SAFE AND EFFECTIVE
CIDOFOVIR USE
Williams, K.M.1, Agwu, A.L.2, Dabb, A.A.3, Higman, M.A.1,
Loeb, D.M.1, Chen, A.R.1 1. Department of Pediatric Oncology, The
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital,
Baltimore, MD; 2. Department of Pediatric Infectious Diseases, Johns
Hopkins Hospital, Baltimore, MD; 3. Department of Pharmacy, Johns
Hopkins Hospital, Baltimore, MD.
Adenoviral infections cause signiﬁcant mortality in bone marrow
transplant (BMT) patients and those with protracted therapy-
induced leukopenia. The mortality from adenovirus in the BMT
population approaches 60% and fatalities have been reported in
oncology patients. Cidofovir (CDV) has emerged as a promising
therapy for adenovirus infection, though its efﬁcacy is reported as
low as 31% with renal toxicity up to 50%. There are no published
clinical algorithms guiding initiation of therapy, and the efﬁcacy
and safety of CDV in pediatric oncology patients are ill-deﬁned. A
clinical algorithm was developed reserving CDV therapy for high-
risk patients, deﬁned as: (1) a BMT patient or a patient with
prolonged leukopenia and (2) evidence of dissemination (blood
PCR or recovery of adenovirus from two or more sites) or
evidence of invasive disease (symptoms associated with the site of
adenoviral disease). A retrospective review of pediatric oncology
and BMT patients with adenoviral infection between July 2001 and
July 2004 captured 20 patients: 9 allogeneic BMT, 3 autologous
BMT, and 8 non-BMT. Using the algorithm, 14 were high risk. Of
these, 9 were treated with CDV. All initially cleared their adeno-
virus though 1 died of fungal infection after recrudescence of
adenovirus. All 5 high-risk CDV untreated patients died, 4 with
disseminated adenovirus. CDV treatment signiﬁcantly reduced ad-
enovirus-related mortality in the high-risk group (RR 0.14, P 
.05). Graft-versus-host disease (GVHD) and hemolytic-uremic
syndrome (HUS) were associated with negative outcomes. All 4
patients with HUS died. Seventy-ﬁve percent of those who died
had severe GVHD. The overall mortality was 45% (9/20), of
which 67% (6/9) was due to adenoviral disease, primarily among
high risk, untreated (5/6) patients. All 6 low-risk patients cleared
their infection without CDV treatment, but one recrudesced and
died of adenoviral disease; he met criteria for treatment at recru-
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